IDB Holding

Innovative Drug Biotech Holdings Limited is a Hong Kong-based investment holding company primarily focused on the biopharmaceutical sector. The company's flagship project is the research and development of an oral insulin enteric-coated soft capsule, which is currently in Phase 3 clinical trials in China. This candidate aims to provide a non-invasive alternative to traditional insulin injections for patients with Type 2 Diabetes, potentially improving patient compliance and quality of life. In addition to its core biotechnology operations, the group is involved in healthcare-related investments, money lending, and the distribution of pharmaceutical products. The company is listed on the Main Board of the Stock Exchange of Hong Kong under the stock code 0397.